alendronate has been researched along with ketoconazole in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS | 1 |
| Arlen, P; Chen, CC; Cox, MC; Cremers, S; Dahut, WL; Figg, WD; Gulley, J; Jones, E; Liewehr, DJ; Liu, Y; Parr, A; Steinberg, SM; Yang, X; Zhai, S | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for alendronate and ketoconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for alendronate and ketoconazole
| Article | Year |
|---|---|
Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
Topics: Acute Disease; Adult; Alendronate; Antifungal Agents; Biomarkers; Bone Density; Collagen; Collagen Type I; Cushing Syndrome; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Prospective Studies | 1998 |
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms | 2005 |
4 other study(ies) available for alendronate and ketoconazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |